Skip to main content
$262.65 $8.48 (3.3%)

12:49 PM EDT on 05/17/22

Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX)

CAPS Rating: 4 out of 5

The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.

Current Price $262.65 Mkt Cap $65.0B
Open $255.82 P/E Ratio 26.61
Prev. Close $254.17 Div. (Yield) $0.00 (0.0%)
Daily Range $254.67 - $262.85 Volume 623,892
52-Wk Range $176.36 - $292.75 Avg. Daily Vol. 1,735,381

Caps

How do you think NASDAQ:VRTX will perform against the market?

Add Stock to CAPS Watchlist

All Players

868 Outperform
70 Underperform
 

All-Star Players

179 Outperform
12 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:VRTX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Kentuckyfarmer (< 20)
Submitted November 29, 2021

Great revenues and lots of potential new things in the pipeline. I’m specifically interested in their investments into genetic and stem cell treatments.

SCOTTRHUETTLCPA (42.16)
Submitted July 22, 2016

9/26/14 DOWN TO UP = <30.04> 7/19/16 = UP TO DOWN

NASDAQ:VRTX VS S&P 500 (SPY)

Fools bullish on NASDAQ:VRTX are also bullish on:

Fools bearish on NASDAQ:VRTX are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about VRTX.

Recs

0
Member Avatar dcrednek (64.94) Submitted: 4/18/2022 6:40:57 PM : Outperform Start Price: $282.99 NASDAQ:VRTX Score: -0.02

Motley Fool Advisors top 10 pick for 4/18/22

Recs

0
Member Avatar tomfoolme (30.62) Submitted: 3/25/2022 2:03:36 PM : Outperform Start Price: $253.30 NASDAQ:VRTX Score: +13.67

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States. 64B pe:27 div:- AS 180/10 Ry/y 27%

Recs

0
Member Avatar chessNstocks (< 20) Submitted: 3/9/2022 11:52:43 AM : Outperform Start Price: $239.32 NASDAQ:VRTX Score: +14.64

From Zacks and Fidelity March 2022
Rev Change (Last Qtr vs Prior year Qtr) = 27.3%
Price/Sales (TTM) = 8.0

Leaderboard

Find the members with the highest scoring picks in VRTX.

Score Leader

bugeyebear

bugeyebear (49.76) Score: +1,465.89

The Score Leader is the player with the highest score across all their picks in VRTX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
bugeyebear 49.76 3/17/2008 Outperform 3Y $14.60 +1,697.47% +231.57% +1,465.89 0 Comment
lostontheprairie 65.48 3/12/2008 Outperform 5Y $14.99 +1,650.70% +218.87% +1,431.83 0 Comment
Kudude 62.70 3/12/2008 Outperform 5Y $14.99 +1,650.70% +218.87% +1,431.83 0 Comment
Salilp 53.96 3/17/2008 Outperform 5Y $15.07 +1,641.41% +234.40% +1,407.01 0 Comment
davidmouw2 < 20 3/14/2008 Outperform NS $15.43 +1,600.78% +218.78% +1,382.00 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. snazzysnazz 71.93 3/13/2008 Outperform 5Y $15.49 +1,594.19% +226.57% +1,367.62 0 Comment
NovaMechanika 30.12 3/20/2008 Outperform 3Y $15.55 +1,587.65% +223.86% +1,363.79 2 Comments
stnewbie 66.18 3/12/2008 Outperform NS $15.78 +1,563.05% +220.32% +1,342.73 0 Comment
PrincetonAl 90.54 3/7/2008 Outperform 3Y $15.86 +1,554.67% +226.52% +1,328.15 1 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. hayrettin 72.04 3/24/2008 Outperform 5Y $16.47 +1,493.38% +215.93% +1,277.45 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for VRTX.